Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$287 Mln
P/E Ratio
--
P/B Ratio
1.97
Industry P/E
--
Debt to Equity
0.14
ROE
-0.63 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.8
CFO
$-280.44 Mln
EBITDA
$-470.96 Mln
Net Profit
$-433.84 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| 2.63 | -40.65 | 3.41 | -22.88 | -37.27 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
ATAI Life Sciences BV (ATAI)
| -46.99 | -65.14 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 46.91 | 3,254.16 | -- | -77.21 | |
| 39.78 | 8,532.22 | 103.89 | 2.27 | |
| 13.82 | 767.89 | -- | -238.46 |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary... psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Address: Wallstrasse 16, Berlin, Germany, 10179 Read more
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board
Mr. Christian Angermayer
Headquarters
Berlin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of ATAI Life Sciences BV (ATAI) stood at $ 217 Mln as on 30-Sep-24
The share price of ATAI Life Sciences BV (ATAI) is $1.37 (NASDAQ) as of 18-Mar-2025 15:33 EDT. ATAI Life Sciences BV (ATAI) has given a return of -37.27% in the last 3 years.
ATAI Life Sciences BV (ATAI) has a market capitalisation of $ 287 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of ATAI Life Sciences BV (ATAI) is 1.97 times as on 17-Mar-2025, a 30% discount to its peers’ median range of 2.83 times.
Since, TTM earnings of ATAI Life Sciences BV (ATAI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the ATAI Life Sciences BV (ATAI) and enter the required number of quantities and click on buy to purchase the shares of ATAI Life Sciences BV (ATAI).
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Address: Wallstrasse 16, Berlin, Germany, 10179
The CEO & director of Mr. Christian Angermayer. is ATAI Life Sciences BV (ATAI), and CFO & Sr. VP is Mr. Christian Angermayer.
There is no promoter pledging in ATAI Life Sciences BV (ATAI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,026
|
|
|
296
|
|
|
76
|
|
|
1,026
|
| ATAI Life Sciences BV (ATAI) | Ratios |
|---|---|
|
Return on equity(%)
|
-68.98
|
|
Operating margin(%)
|
-36877.34
|
|
Net Margin(%)
|
-38852.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of ATAI Life Sciences BV (ATAI) was $0 Mln.
$-0.10
(
